These two landmark trials continue a promising shift away from a historical glucose- or weight loss-centric focus in the treatment of T2D and obesity, respectively, further emphasizing the substantial benefits of GLP-1 medicines in reducing serious cardiorenal complications, morbity, and mortality in people living with T2D and/or obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.